Previous 10 | Next 10 |
IMV (IMV) plummets 17% premarket after pricing its public offering of 14,285,714 units at $1.75/unit, for aggregate gross proceeds of ~$25M.Each unit comprises of one common share and three-quarters of one common share purchase warrant. Net proceeds will be used to continue the clin...
IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, has filed today a preliminary prospectus supplement (the “Supplement”) to its final short form base shelf prospectus dated June 26, 2020...
Stocks continue to rally in 2021. June is the sixth month in a row the TSX Composite Index has reached a fresh record high. Nonetheless, some tiny stocks still look undervalued. Bay Street analysts expect some of these stocks to more than double in the next 12 months. Most of these ...
Clinical-stage biopharmaceutical company IMV (IMV) announces the appointment of Jeremy Graff as the company's chief scientific officer, effective as of June 14, 2021. Graff brings over 20 years of experience in preclinical and clinical research and translational analy...
Dr. Graff will lead IMV’s research to continue the expansion of DPX- based immuno-oncology pipeline and the development of a comprehensive translational strategy to optimize clinical success Industry veteran Stanley Frankel, M.D. to advise on clinical development ...
For questions or voting your shares, please contact Laurel Hill Advisory Group at 1-877-452-7184 or by email at assistance@laurelhill.com IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company...
IMV (TSX:IMV) (NASDAQ:IMV) is a biopharmaceutical company focused on improving the treatment of cancer . The company gives patients with hard-to-treat cancers a chance to enjoy a long and healthy life. IMV uses a drug delivery platform (DPX) technology, to achieve targeted s...
Image source: The Motley Fool. IMV Inc. (NASDAQ: IMV) Q1 2021 Earnings Call May 12, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: IMV Inc. (IMV) Q1 2021 Earnings Call Transcript
Start Time: 08:00 End Time: 08:40 IMV Inc. (IMV) Q1 2021 Earnings Conference Call May 12, 2021, 08:00 AM ET Company Participants Fred Ors - CEO Pierre Labbé - CFO Andrew Hall - Chief Business Officer Conference Call Participants Kaveri Pohlman - BTIG Joe Pantginis - H.C. Wainwright Ted T...
The following slide deck was published by IMV Inc. in conjunction with their 2021 Q1 earnings call. For further details see: IMV Inc. 2021 Q1 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
GAAP Net Income of $8.3 million or $0.25 per diluted share Non-GAAP Net Income of $11.0 million or $0.33 per diluted share Declares Third Consecutive Quarterly Dividend Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, to...
IMV Inc. (the “ Company ” or “ IMV ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced tha...
Horizon Technology Finance Announces First Quarter 2023 Financial Results PR Newswire - First Quarter 2023 Net Investment Income per Share of $0.46 ; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to ...